aaaccchhhhh,,,the best we can hope for is the covid19 data gives us a bump in share price while we tinker with expanding the benefits of apabetalone around covids and other similar MOA diseases,,,,,,while the new partner takes the bull by the horns on the BoM2 side,,,this is a scenario which should be expected but knowing the lack of business sense within its not likely to happen. It is sort of the idea I had always hoped for where the molecules in wait are working their magic with other partnering arrangements in a concurrent fashion! But that has been a utopian dream!! and undoubtedly will remain so as long as little attention gets paid to moving forward and their inability to build any amount of shareholder value in the market!